SCHEMBL6281952

SCHEMBL6281952

CN1CCN(S(=O)(=O)c2ccc(-c3ccc(F)cc3)cc2)C(C(=O)NO)C1

nearest known ligand 0.70

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
MMP3 P08254 9/20 0.70
MMP9 P14780 8/20 0.70
MMP1 P03956 8/20 0.70
MMP13 P45452 8/20 0.70
MMP7 P09237 7/20 0.70
MMP2 P08253 2/20 0.56
MMP8 P22894 2/20 0.53
ADAM17 P78536 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6281943 1.00 MMP3 (0.70) MMP3MMP9MMP1MMP13MMP7
SCHEMBL6337327 0.90 MMP1 (0.76) MMP3MMP9MMP1MMP13MMP7
SCHEMBL6337331 0.90 MMP1 (0.76) MMP3MMP9MMP1MMP13MMP7
Hydrochloric Acid SCHEMBL6264440 0.87 MMP3 (0.69) MMP3MMP9MMP1MMP13MMP7
SCHEMBL6498571 0.83 MMP1 (0.55) MMP3MMP9MMP1MMP13MMP7
SCHEMBL27560678 0.82 MMP1 (0.75) MMP3MMP9MMP1MMP13MMP7
SCHEMBL778773 0.81 MMP1 (0.63) MMP3MMP9MMP1MMP13MMP7
SCHEMBL6752977 0.80 MMP13 (0.78) MMP3MMP9MMP1MMP13MMP7
SCHEMBL6338650 0.80 MMP1 (0.78) MMP3MMP9MMP1MMP13MMP7
SCHEMBL6265752 0.80 MMP1 (0.78) MMP3MMP9MMP1MMP13MMP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1596846-A2 INHIBITORS OF HEPATITIS C VIRUS, COMPOSITIONS AND TREATMENTS USING THE SAME PFIZER INC. (US) 2005-11-23 EP claimed
US-20040229817-A1 Inhibitors of Hepatitis C virus, compositions and treatments using the same AGOURON PHARMACEUTICALS, INC. 2004-11-18 US claimed
WO-2004073599-A2 INHIBITORS OF HEPATITIS C VIRUS, COMPOSITIONS AND TREATMENTS USING THE SAME PFIZER INC. (US) 2004-09-02 WO claimed
EP-1098662-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2001-05-16 EP claimed
WO-2000004892-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2000-02-03 WO claimed
WO-2004093860-A1 INHIBITORS OF SARS RELATED CORONAVIRUS PROTEINASE PFIZER INC. (US) 2004-11-04 WO disclosed
EP-1098662-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2001-05-16 EP disclosed
WO-2000004892-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229817-A1 Inhibitors of Hepatitis C virus, compositions and treatments using the same TIMP3, MMP2, MMP7 MMP3 5/4885MMP9 14/4885MMP1 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.